Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,400 shares, a decrease of 7.7% from the October 31st total of 2,600 shares. Based on an average daily trading volume, of 4,100 shares, the short-interest ratio is currently 0.6 days.

Advaxis Price Performance

ADXS stock opened at $1.66 on Monday. Advaxis has a 12 month low of $1.02 and a 12 month high of $30.56. The firm has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $2.49. The firm has a market cap of $3.01 million, a PE ratio of -16.55 and a beta of 2.07.

Advaxis (OTCMKTS:ADXS – Get Rating) last posted its earnings results on Monday, September 12th. The biotechnology company reported ($3.83) earnings per share for the quarter.

Analyst Ratings Changes

Advaxis Company Profile

(Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Featured Stories

• Get a free copy of the StockNews.com research report on Advaxis (ADXS)
• Intel is a Sleeping Giant Ready to Awaken
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.